Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of PRKAA2 and LKB1 genetic variants on metabolic alterations in response to metformin-sulfonylurea therapy.

Biomarkers in medicine - 1 Jan 2026

Rizvi Aliya Abbas, Abbas Mohammad, Ansari Asma Imran, Verma Sushma, Siddiqi Zeba, Mahdi Farzana

Abstract excerpt

BACKGROUND: Metformin-sulfonylurea combination is a widely prescribed as second-line therapy for type 2 diabetes mellitus (T2DM), yet patient responses vary due to individual genetic variation. These variations, particularly in AMP-activated protein kinase (AMPK) and its upstream regulator liver kinase B1 (LKB1), may contribute to differences in treatment response. This study investigated the association of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to AMP-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to AMP-Activated Protein Kinases

Share to Diabetes Mellitus, Type 2

Share to Hypoglycemic Agents

Share to Metformin

Share to Protein Serine-Threonine Kinases

Share to Sulfonylurea Compounds

Source

Open in PubMed Open full text

Identifiers

PMID: 41467564
DOI: 10.1080/17520363.2025.2608954
PMCID: PMC12947565

Genes

PRKAA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of PRKAA2 and LKB1 genetic variants on metabolic alterations in response to metformin-sulfonylurea therapy.PMID 41467564Read ↗

Evaluation of PRKAA2 Genetic Variation on Metformin Efficacy as an Initial Therapy Among Drug-Naïve Patients With Type II Diabetes MellitusSemantic proximity Read ↗

Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program.Semantic proximity Read ↗

Haplotype structures and large-scale association testing of the 5' AMP-activated protein kinase genes PRKAA2, PRKAB1, and PRKAB2 [corrected] with type 2 diabetes.Semantic proximity Read ↗

RAP1A Variant rs7525578 Modifies Glycemic Response to Metformin But Not to Pioglitazone or Gliclazide in the UK Biobank.Semantic proximity Read ↗

Effect of AMP-activated protein kinase subunit alpha 2 (PRKAA2) genetic polymorphisms on susceptibility to type 2 diabetes mellitus and diabetic nephropathy in a Chinese population.Semantic proximity Read ↗

A novel polymorphism in protein kinase AMP-activated catalytic subunit alpha 2 (PRKAA2) is associated with type 2 diabetes in the Han Chinese population.Semantic proximity Read ↗

Pharmacogenetics of Oral Antidiabetic DrugsSemantic proximity Read ↗

Implications of genetic variations, differential gene expression, and allele-specific expression on metformin response in drug-naïve type 2 diabetes.Semantic proximity Read ↗

Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes.Semantic proximity Read ↗

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.Semantic proximity Read ↗

AMPK Subunits Harbor Largely Nonoverlapping Genetic Determinants for Body Fat Mass, Glucose Metabolism, and Cholesterol MetabolismSemantic proximity Read ↗

Adiponectin gene polymorphism rs2241766 T/G is associated with response to pioglitazone treatment in type 2 diabetic patients from southern China.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.